MIDAZOLAM
Opioid Use
University of CreteSmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 89/ 100
Competitive context
32 Active assets in the Opioid Use cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE Wake Forest University Health Sciences | Phase 4 | BBB |
Bxcl501 Kaohsiung Veterans General Hospital. | Phase 4 | BB |
FENTANYL University of Crete | Phase 4 | BB |
LIDOCAINE Tanta University | Phase 4 | BB |
Oxycodone Wake Forest University Health Sciences | Phase 4 | BB |
View all 38 →
Same molecule, other indications
MIDAZOLAM is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →